OUR PRODUCTS
- Each film-coated tablet contains 1.6975 mg pyridinopril equivalent to 2.5 mg pyridinopril arginine + 0.625 mg indapamide + 6.935 mg amlodipine besylate equivalent to 5 mg amlodipine.
- Each film coated tablet contains 3.395 mg pyridinopril equivalent to 5 mg arginine pyridinopril + 1.25 mg indapamide + 6.935 mg amlodipine besylate equivalent to 5 mg amlodipine.
- Each film-coated tablet contains 3.395 mg pyridinopril equivalent to 2.5 mg pyridinopril arginine + 1.25 mg indapamide + 13.870 mg amlodipine besylate equivalent to 10 mg amlodipine.
- Each film coated tablet contains 6.790 mg pyridinopril equivalent to 10 mg pyridinopril arginine + 2.5 mg indapamide + 6.935 mg amlodipine besylate equivalent to 5 mg amlodipine.
- Each film coated tablet contains 6.790 mg pyridinopril equivalent to 10 mg pyridinopril arginine + 2.5 mg indapamide + 13.870 mg amlodipine besylate equivalent to 10 mg amlodipine.
- Dialysis patients
- Patients with untreated decompensated heart failure
- Severe renal impairment (creatinine clearance less than 30 ml/min)
- Hypersensitivity to the active substances, to other sulfonamides, to dihydropyridine derivatives, to any other ACE inhibitor or to any of the excipients.
- History of angioedema associated with previous treatment with ACE inhibitors
- Hereditary / idiopathic angioedema
- The second and third trimesters of pregnancy
- Breastfeeding
- Hepatic encephalopathy
- Severe hepatic failure
- Hypokalemia
- Severe hypotension
- Shock, including cardiogenic shock
- Left ventricular duct obstruction (eg, high-grade aortic stenosis)
- Hemodynamically unstable heart failure after acute myocardial infarction
- Concomitant use with sacubitril / valsartan
- Drugs that cause hyperkalemia: Certain drugs or therapeutic classes may increase the incidence of hyperkalemia: aliskiren, potassium salts, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, NSAIDs, heparin, agents Immunosuppressants such as cycloprolosporin or trimoprolosporin. The combination of these medicines increases the risk of developing hyperkalemia.
- Concomitant use with aliskiren is contraindicated: in patients with diabetes or patients with renal insufficiency, the risk of hyperkalemia, deterioration of renal function, cardiovascular morbidity and mortality increases.
- Sacubitril/Valsartan: Concomitant use of perindopril and sacubitril/valsartan may increase the risk of angioedema. Sacubitril/valsartan should not be started until 36 hours after your last dose of perindopril treatment.
- Reversible increases in serum lithium concentrations and toxicity have been reported while taking lithium with ACE inhibitors. The use of perindopril with indapamide and lithium is not recommended.
- Patients taking concomitant cotrimoxazole (trimethoprim/sulfamethoxazole) are at increased risk of developing hyperkalemia.
- Concomitant treatment with allopurinol and indapamide may increase the incidence of hypersensitivity reactions to allopurinol.
- It is an antihypertensive medicine used to treat high blood pressure (hypertension).
- Each of the main active substances reduces blood pressure and works together to control blood pressure:
Perindopril belongs to a class of medicines called angiotensin-converting enzyme (ACE) inhibitors.
It works by dilating the blood vessels
Indapamide is a diuretic (belongs to a class of medicines called sulfonamide derivatives with
indole ring). Diuretics increase the amount of urine excreted by the kidneys. However, indapamide
It differs from other diuretics, in that it causes only a slight increase in the amount of urine produced.
Amlodipine is a calcium channel blocker (which belongs to a class of medicines called dihydropyridines).
It works by relaxing the blood vessels s
Dosage:
- One film-coated tablet daily as a single dose, preferably before the meal in the morning.
- The fixed-dose combination is not suitable for initial therapy.
- If a mode change is required, calibration should be carried out using individual components
- Renal impairment: In severe renal impairment (creatinine clearance less than 30 ml/min), it is contraindicated.
- Patients with moderate renal insufficiency (creatinine clearance 30-60 ml/min) each of 10/2.5/5 mg and 10/2.5/10 mg are contraindicated. The usual medical follow-up includes frequent monitoring of creatinine and potassium.
- Hepatic insufficiency: In cases of severe hepatic insufficiency, this drug is contraindicated. In patients with mild to moderate hepatic insufficiency, this drug should be given with caution and with continuous monitoring.
- Elderly: The excretion of predinopril decreases in the elderly. Treatment with this medicine follows the functioning of the kidneys.
- Children: The safety and efficacy of Triblvasc in children and adolescents has not been established.
sudden wheezing, chest pain, shortness of breath, swelling of the eyelids, face and lips, swelling of the mouth, tongue and throat, severe skin rash, itching, blistering, peeling and swelling of the skin, Stevens-Jenson syndrome, dizziness, rapid heartbeat and life-threatening irregular heartbeat, confusion Vision, tinnitus, anxiety, depression, hair loss, increased frequency of urination, fever, changes in weight .